Supernus Announces Second Quarter 2024 Financial Results
06 Aug 2024 //
GLOBENEWSWIRE
Supernus Announces First Quarter 2024 Financial Results
08 May 2024 //
GLOBENEWSWIRE
FTC says patent battle over Parkinson`s drug have `significant implications`
21 Mar 2023 //
ENDPTS
Enforcement Report - Week of February 1, 2023
01 Feb 2023 //
FDA
FDA rejects Supernus’ drug infusion device for Parkinson’s
11 Oct 2022 //
BIOPHARMADIVE
Celera`s apomorphine therapy device for Parkinson’s set as alternative to DBS
09 Mar 2022 //
PHARMABIZ
TruPharma Announces Approval and Launch of Apomorphine Hydrochloride Cartridges
01 Mar 2022 //
PRNEWSWIRE
Sage Pharms` Generic Apomorphine Hydrochloride Receives Approval in the U.S.
23 Feb 2022 //
FDA
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830
22 Feb 2022 //
GLOBENEWSWIRE
Sunovion and BIAL Enter European Licensing Agreement
02 Sep 2021 //
BUSINESSWIRE
Sunovion Announces the Commercial Launch of KYNMOBI™
03 Oct 2020 //
BIOSPACE
Sunovion Announces Health Canada Approval of KYNMOBI™
15 Jun 2020 //
BIOSPACE
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride)
27 May 2020 //
BUSINESSWIRE
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride)
23 May 2020 //
BUSINESSWIRE
Parkinson`s patients no longer need to rely on a needle for apomorphine
22 May 2020 //
ENDPTS
Supernus to Acquire CNS Portfolio from US WorldMeds
28 Apr 2020 //
GLOBENEWSWIRE
Sunovion receives CRL for its Parkinson’s NDA
05 Feb 2019 //
IN-PHARMATECHNOLOGIST
Rusan Pharma launches DCGI approved Aposan to treat Parkinson’s disease
14 Dec 2018 //
PHARMABIZ
Sunovion’s Parkinson’s disease drug is a step closer to approval
27 Jun 2018 //
PHARMAPHORUM
FDA to review Sunovion’s apomorphine sublingual film for Parkinson’s disease
14 Jun 2018 //
DRUG DELIVERY
Sunovion Submits NDA to the FDA for Apomorphine Sublingual Film (APL-130277)
30 Mar 2018 //
BUSINESSWIRE